Kymab Limited discovers, develops, and commercializes human therapeutic monoclonal antibodies for the treatment of human diseases using its proprietary Kymouse platform. Its platform captures the diversity of the B lymphocyte component of the human immune system and generates human antibody-based biopharmaceuticals directed against clinically precedented drug targets and drugs against novel targets. The company was incorporated in 2009 and is based in Cambridge, the United Kingdom.